News

Life Sciences

Edward Kim | Equities.com |

Deal was more than doubled in size, priced at $17 and never traded below $28.


Edward Kim | Equities.com |

The result is an important step toward a diabetes treatment that restores the body’s ability to produce insulin.


Edward Kim | Equities.com |

XTANDI shows statistically significant improvement in OS in patients with non-metastatic, castration-resistant prostate cancer.


Edward Kim | Equities.com |

New two-year data supports Eylea's use in preventative setting in diabetic retinopathy.


Edward Kim | Equities.com |

Artificial intelligence points to a rheumatoid arthritis drug that may be a viable treatment for the new virus.


Reuters | Equities.com |

The drugmaker expects the two new treatments to bring in combined revenue of $1.7 billion in 2020.


Edward Kim | Equities.com |

Risdiplam showed medically-meaningful and statistically significant results patients with type 2 and type 3 SMA.


Edward Kim | Equities.com |

Company's earnings missed estimates. Separation plan will take two years.


AP News | Equities.com |

Women's health and some of its older drugs and biosimilars to be spun off into a new company via tax-free distribution to shareholders.


Edward Kim | Equities.com |

2.5% of the pediatric population suffers from peanut allergies.



Discover: Trending Events

United Nations
Blockchain for Europe
Humanity 2.0
World Economic Forum